IMPL - Impel Pharmaceuticals Inc
Close
0.2411
-0.173 -71.796%
Share volume: 858,521
Last Updated: Fri 15 Dec 2023 10:00:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.41
-0.17
-41.79%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-16 | 2022-08-15 | 2022-11-14 | 2023-03-27 | 2023-05-12 | 2023-08-18 | 2023-11-14 | |
| Assets | ||||||||
| Total Assets | 147.799 M | 120.434 M | 105.172 M | 88.550 M | 64.729 M | 44.807 M | 35.073 M | |
| Current Assets | 142.184 M | 114.432 M | 99.276 M | 79.809 M | 51.884 M | 32.904 M | 23.427 M | |
| Inventories | 5.496 M | 6.929 M | 8.622 M | 8.427 M | 8.014 M | 6.985 M | 6.864 M | |
| Other Current Assets | 2.965 M | 4.882 M | 4.794 M | 3.284 M | 2.125 M | 3.956 M | 5.236 M | |
| Short Term Investments | 2.965 M | 4.882 M | 4.794 M | 3.284 M | 2.125 M | 3.956 M | 5.236 M | |
| Total Receivables | 3.886 M | 4.794 M | 6.129 M | 7.444 M | 6.280 M | 6.801 M | 6.586 M | |
| Current Cash | 129.837 M | 97.827 M | 79.731 M | 60.654 M | 35.465 M | 15.162 M | 239.000 K | |
| Total Non-current Assets | 5.615 M | 6.002 M | 5.896 M | 8.741 M | 12.845 M | 11.903 M | 11.646 M | |
| Property Plant Equipment | 2.847 M | 2.769 M | 2.776 M | 3.863 M | 4.081 M | 3.944 M | 4.087 M | |
| Other Assets | 2.768 M | 3.233 M | 3.120 M | 4.878 M | 8.764 M | 7.959 M | 7.559 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 147.799 M | 120.434 M | 105.172 M | 88.550 M | 64.729 M | 44.807 M | 35.073 M | |
| Total liabilities | 120.317 M | 116.524 M | 127.461 M | 132.707 M | 137.634 M | 123.965 M | 126.978 M | |
| Total current liabilities | 23.980 M | 18.295 M | 19.963 M | 22.163 M | 22.282 M | 121.221 M | 124.743 M | |
| Accounts Payable | 8.995 M | 4.747 M | 4.751 M | 6.092 M | 6.133 M | 3.458 M | 3.734 M | |
| Other liabilities | 405.000 K | 863.000 K | 1.890 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 2.568 M | 3.794 M | 3.111 M | 3.568 M | 4.426 M | 105.945 M | 112.563 M | |
| Long term debt | 95.932 M | 97.366 M | 105.608 M | 110.544 M | 115.352 M | 2.744 M | 2.235 M | |
| Other liabilities | 405.000 K | 863.000 K | 1.890 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 27.482 M | 3.910 M | -22.289 M | -44.157 M | -72.905 M | -79.158 M | -91.905 M | |
| Common stock | 23.144 M | 23.178 M | 23.710 M | 23.749 M | 23.746 M | 23.748 M | 23.749 M | |
| Retained earnings | -241.768 M | -266.972 M | -298.069 M | -321.110 M | -351.177 M | -358.534 M | -372.348 M |